ONO-1110 + Placebo

Phase 2Active

1 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Social Anxiety Disorder (SAD)

Conditions

Social Anxiety Disorder (SAD)

Trial Timeline

Jan 16, 2025 → Oct 31, 2026

NCT ID

NCT06805565

About ONO-1110 + Placebo

ONO-1110 + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Social Anxiety Disorder (SAD). The current trial status is active. This product is registered under clinical trial identifier NCT06805565. Target conditions include Social Anxiety Disorder (SAD).

What happened to similar drugs?

7 of 16 similar drugs in Social Anxiety Disorder (SAD) were approved

Approved (7) Terminated (4) Active (6)

✅Cariprazine + PlaceboAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅quetiapineAstraZenecaApproved

✅Pristiq + PlaceboPfizerApproved

✅Sertraline + PlaceboPfizerApproved

✅NefazodoneBristol Myers SquibbApproved

✅EscitalopramLundbeckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06752603	Phase 2	Recruiting	Apr 2, 2025	Aug 1, 2026	Hunner Type Interstitial Cystitis
NCT06752590	Phase 2	Recruiting	Mar 26, 2025	Sep 1, 2026	Fibromyalgia
NCT06708416	Phase 2	Active	Feb 12, 2025	Aug 31, 2026	Postherpetic Neuralgia
NCT06805565	Phase 2	Active	Jan 16, 2025	Oct 31, 2026	Social Anxiety Disorder (SAD)
NCT06792136	Phase 2	Active	Jan 16, 2025	Aug 31, 2026	Major Depressive Disorder (MDD

Competing Products

20 competing products in Social Anxiety Disorder (SAD)

See all competitors

Product	Company	Stage	Hype Score
LY686017 + paroxetine + placebo	Eli Lilly	Phase 2	35
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
Cariprazine + Placebo	AbbVie	Approved	43
Quetiapine	AstraZeneca	Approved	43
quetiapine	AstraZeneca	Phase 3	32
quetiapine	AstraZeneca	Phase 2/3	38
Seroquel + Sugar Pill	AstraZeneca	Phase 3	40
quetiapine	AstraZeneca	Approved	43
Pristiq + Placebo	Pfizer	Approved	43
Venlafaxine ER	Pfizer	Phase 3	40
Ziprasidone + Sertraline	Pfizer	Phase 2	35
Sertraline + Placebo	Pfizer	Approved	35
Nefazodone	Bristol Myers Squibb	Approved	43
Escitalopram	Lundbeck	Approved	40
Cipralex + Placebo	Lundbeck	Phase 2	32
BHV-0223 + Placebo	Biohaven	Phase 2/3	32
VQW-765 + Placebo	Vanda Pharmaceuticals	Phase 3	37
PH94B	Vistagen Therapeutics	Phase 3	22
Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray	Vistagen Therapeutics	Phase 2	32
PH94B Nasal Spray + Placebo Nasal Spray	Vistagen Therapeutics	Phase 3	22